135 results on '"Krueger, Julie"'
Search Results
2. Meeting His Needs
3. Mechanistic MALDI-TOF Cell-Based Assay for the Discovery of Potent and Specific Fatty Acid Synthase Inhibitors
4. Implementation of caregiver depression screening in an urban, community-based asthma clinic: a quality improvement project
5. Association between social needs and asthma control among children evaluated at a single-center high-risk asthma clinic
6. Abstract 6268: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy
7. Barriers to Infant Preventive Care During the COVID-19 Pandemic
8. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia
9. Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability
10. Barriers to Infant Preventive Care During the COVID-19 Pandemic.
11. Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines
12. Emergency Department Use for Non-emergent Asthma-related Symptoms
13. The Harasser’s Toolbox: Investigating the Role of Mobility in Street Harassment
14. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities
15. The Harasser's Toolbox: Investigating the Role of Mobility in Street Harassment.
16. Remote monitoring goes live on the network
17. P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position
18. Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors
19. A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site
20. The Road to Disbelief: A Study of the Atheist De-Conversion Process
21. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles
22. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice
23. The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model
24. Neutralization of Plasminogen Activator Inhibitor I (PAI-1) by the Synthetic Antagonist PAI-749 via a Dual Mechanism of Action
25. Cyclopropylamino Acid Amide as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B1 Receptor Antagonists
26. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 1: Weakly basic azoles
27. Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization
28. P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold
29. 9-Hydroxyazafluorenes and Their Use in Thrombin Inhibitors
30. Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability
31. Discovery and Evaluation of Potent P1 Aryl Heterocycle-Based Thrombin Inhibitors
32. Unexpected enhancement of thrombin inhibitor potency with o -aminoalkylbenzylamides in the P1 position
33. Design and synthesis of potent and selective macrocyclic thrombin inhibitors
34. Small, Low Nanomolar, Noncovalent Thrombin Inhibitors Lacking a Group to Fill the “Distal Binding Pocket”.
35. Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. implementation of P3 pyridine N-Oxides to deliver an orally bioavailable series containing P1 N-Benzylamides
36. 3-Amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors
37. Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors
38. Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines
39. Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the ‘Distal binding pocket’
40. Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors
41. P 2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold
42. Selective Inhibition of Factor Xa in the Prothrombinase Complex by the Carboxyl-terminal Domain of Antistasin
43. Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates
44. Design and Synthesis of a Series of Potent and Orally Bioavailable Noncovalent Thrombin Inhibitors That Utilize Nonbasic Groups in the P1 Position
45. L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor
46. Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position
47. Synthesis of a Series of Potent and Orally Bioavailable Thrombin Inhibitors That Utilize 3,3-Disubstituted Propionic Acid Derivatives in the P3 Position
48. Dissecting the Effects of DNA Polymerase and Ribonuclease H Inhibitor Combinations on HIV-1 Reverse-Transcriptase Activities.
49. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR–/– and apoE–/– mice
50. Cyclopropylamino Acid Amide as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B1 Receptor Antagonists
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.